


1 Non-Stimulant vs. placebo

1.1 ADHD-symptoms (critical)


Study or Subgroup	non-stimulants		Placebo		Total	Weight	Mean Difference IV, Random, 95% CI	Risk of Bias
	Mean	SD	Mean	SD				
Total (95% CI)	0		0		0		Not estimable	

Heterogeneity: Not applicable
 Test for overall effect: Not applicable

Risk of bias legend




1.2 Psychotic symptoms (critical)




Footnotes


- (1) Modafinil, PANSS positive, lower is better
- (2) Atomoxetine, BPRS, lower is better
- (3) Modafinil, Afloest på graf (fig 3), PANSS positive, lower is better
- (4) Atomoxetine, PANSS positive, lower is better
- (5) modafinil, Data from LOCF. SAPS (scale for assessment of positive symptoms), lower is better
- (6) Atomoxetine, Data from observed cases, PANSS, lower is better



1.4 Global symptoms/functioning (important)



1.5 Psychiatric hospitalization



Footnotes


(1) Modafinil

1.6 Executive functions (important)


Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Std. Mean Difference IV, Random, 95% CI	Risk of Bias
	Mean	SD	Mean	SD				
1.6.1 Final score								
Lohr, 2013 (1)	0.12	0.6928	-0.19	0.7275	12	41.0%	0.42 [-0.39, 1.23]	
Subtotal (95% CI)	12				12	41.0%	0.42 [-0.39, 1.23]	
Heterogeneity: Not applicable Test for overall effect: Z = 1.02 (P = 0.31)								
1.6.7 Change score								
Friedman 2008 (2)	0.31	0.64	7	0.02	0.87	8	25.6%	0.35 [-0.67, 1.38]
Kelly, 2009 (3)	0.15	0.89	8	-0.05	0.66	12	33.4%	0.25 [-0.65, 1.15]
Subtotal (95% CI)	15				20	59.0%	0.30 [-0.38, 0.97]	
Heterogeneity: Tau ² = 0.00; Chi ² = 0.02, df = 1 (P = 0.89); I ² = 0% Test for overall effect: Z = 0.86 (P = 0.39)								
Total (95% CI)	27				32	100.0%	0.35 [-0.17, 0.87]	
Heterogeneity: Tau ² = 0.00; Chi ² = 0.07, df = 2 (P = 0.96); I ² = 0% Test for overall effect: Z = 1.31 (P = 0.19) Test for subgroup differences: Chi ² = 0.05, df = 1 (P = 0.82), I ² = 0%								

Footnotes:
 (1) Modafinil, NP-composite executive,
 (2) Atomoxetine, Tower of London, change score,
 (3) Woodcock-Johnson planning test, z-score change


1.7 Attention (important)



1.8 Extrapyramidal side effects (important)





1.9 Extrapryramidal side effects (important)





Footnotes

- (1) atomoxetine, Simpson Angus Scale, Lower is better
- (2) Modafinil, SAS, aflæst på fig 2 day-56, final score, lower is better
- (3) Modafinil, Simpson Angus Scale, final score, lower is better
- (4) atomoxetine, Simpson Angus Extrapryramidal symptoms Scale, umiddelbart change score
- (5) Modafinil, Modified Simpson Angus Scale, change










1-10.34 Euphoric mood			
Subtotal (95% CI)	0	0	0
Total events	0	0	0
Heterogeneity: Not applicable			
Test for overall effect: Not applicable			
1-10.35 Psychotic disorders			
Subtotal (95% CI)	0	0	0
Total events	0	0	0
Heterogeneity: Not applicable			
Test for overall effect: Not applicable			




Test for subgroup differences: Chi² = 21.77, df = 27 (P = 0.75), I² = 0%

Footnotes

- (1) Modafinil
- (2) atomoxetine
- (3) Modafinil
- (4) Modafinil
- (5) Modafinil
- (6) atomoxetine
- (7) atomoxetine
- (8) modafinil
- (9) atomoxetine
- (10) atomoxetine
- (11) atomoxetine
- (12) Modafinil
- (13) Modafinil
- (14) Modafinil
- (15) atomoxetine
- (16) Modafinil
- (17) Modafinil
- (18) atomoxetine
- (19) atomoxetine
- (20) atomoxetine
- (21) Modafinil
- (22) atomoxetine
- (23) Modafinil
- (24) Modafinil
- (25) atomoxetine
- (26) Modafinil
- (27) Modafinil
- (28) Modafinil
- (29) atomoxetine
- (30) atomoxetine
- (31) atomoxetine
- (32) atomoxetine
- (33) atomoxetine
- (34) atomoxetine
- (35) atomoxetine
- (36) atomoxetine
- (37) Modafinil
- (38) atomoxetine
- (39) atomoxetine

1.11 Suicidal behavior (important)

Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Risk Ratio		Risk Ratio	Risk of Bias
	Events	Total	Events	Total			M-H, Random, 95% CI	M-H, Random, 95% CI		
Total (95% CI)	0	0	0	0	0	0	Not estimable			
Total events	0	0	0	0						
Heterogeneity: Not applicable										
Test for overall effect: Not applicable										



Risk of bias legend

1.12 Substance use (important)


Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Risk Ratio		Risk Ratio	Risk of Bias
	Events	Total	Events	Total			M-H, Random, 95% CI	M-H, Random, 95% CI		
Total (95% CI)	0	0	0	0	0	0	Not estimable			
Total events	0	0	0	0						
Heterogeneity: Not applicable										
Test for overall effect: Not applicable										



Risk of bias legend

1.13 Post hoc: Serious adverse events


Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Odds Ratio		Odds Ratio	Risk of Bias
	Events	Total	Events	Total			M-H, Random, 95% CI	M-H, Random, 95% CI		
Freudenreich 2009 (1)	1	19	1	16	100.0%	0.83	[0.05, 14.48]			
Total (95% CI)	1	19	1	16	100.0%	0.83	[0.05, 14.48]			
Total events	1	1	1	1						
Heterogeneity: Not applicable										
Test for overall effect: Z = 0.13 (P = 0.90)										



Footnotes


(1) Modafinil

1.14 Post hoc: worsening psychosis




3 Sensitivitätsanalyse: Non-Stimulant vs. placebo


3.1 ADHD-symptoms (critical)




3.2 Psychotic symptoms (critical)




Footnotes
 (1) Modafinil, PANSS positive, lower is better
 (2) Atomoxetine, BPRS, lower is better
 (3) Modafinil, Aflaest på graf (fig 3), PANSS positive, lower is better
 (4) Atomoxetine, Data from observed cases, PANSS, lower is better




3.4 Globally symptoms/functioning (important)



3.5 Psychiatric hospitalization




3.6 Executive functions (important)




Footnotes:
 (1) Modafinil, NP-composite executive,
 (2) Atomoxetine, Tower of London, change score,
 (3) Woodcock-Johnson planning test, z-score change


3.7 Attention (important)




3.8 Extrapyramidal side effects (important)





3.9 Extrapyramidal side effects (important)




(1) atomoxetine, Simpson Angus Scale, Lower is better
 (2) Modafinil, SAS, afkast på fig 2 day-56, final score, lower is better
 (3) Modafinil, Modified Simpson Angus Scale, change









3.10.35 Psychotic disorders

Subtotal (95% CI) 0 0 0 0 Not estimable

Total events 0 0 0 0


Heterogeneity: Not applicable

Test for overall effect: Not applicable

Test for subgroup differences: Chi² = 19.56, df = 23 (P = 0.67), I² = 0%


Footnotes

- (1) Modafinil
- (2) atomoxetine
- (3) Modafinil
- (4) Modafinil
- (5) atomoxetine
- (6) atomoxetine
- (7) modafinil
- (8) atomoxetine
- (9) atomoxetine
- (10) atomoxetine
- (11) Modafinil
- (12) Modafinil
- (13) Modafinil
- (14) atomoxetine
- (15) Modafinil
- (16) atomoxetine
- (17) atomoxetine
- (18) Modafinil
- (19) atomoxetine
- (20) atomoxetine
- (21) Modafinil
- (22) Modafinil
- (23) atomoxetine
- (24) atomoxetine
- (25) atomoxetine
- (26) atomoxetine
- (27) atomoxetine
- (28) atomoxetine
- (29) atomoxetine
- (30) atomoxetine
- (31) Modafinil
- (32) atomoxetine
- (33) atomoxetine



3.11 Suicidal behavior (important)

Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI	Risk of Bias
	Events	Total	Events	Total					
Total (95% CI)	0	0	0	0	0	0	Not estimable		
Total events	0	0	0	0	0				
Heterogeneity: Not applicable									
Test for overall effect: Not applicable									



Risk of bias legend

3.12 Substance use (important)


Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI	Risk of Bias
	Events	Total	Events	Total					
Total (95% CI)	0	0	0	0	0	0	Not estimable		
Total events	0	0	0	0	0				
Heterogeneity: Not applicable									
Test for overall effect: Not applicable									



Risk of bias legend

3.13 Post hoc: Serious adverse events

Study or Subgroup	Non-stimulant		Placebo		Total	Weight	Odds Ratio M-H, Random, 95% CI	Odds Ratio M-H, Random, 95% CI	Risk of Bias
	Events	Total	Events	Total					
Freudenreich 2009 (1)	1	19	1	16	100.0%	0.83 [0.05, 14.48]	0.83 [0.05, 14.48]		
Total (95% CI)	1	19	1	16	100.0%	0.83 [0.05, 14.48]	0.83 [0.05, 14.48]		
Total events	1	1	1	1					
Heterogeneity: Not applicable									
Test for overall effect: Z = 0.13 (P = 0.90)									



Footnotes

(1) Modafinil

3.14 Post hoc: worsening psychosis

Study or Subgroup	non-stimulant		Placebo		Total	Weight	Risk Ratio	
	Events	Total	Events	Total			M-H, Random, 95% CI	M-H, Random, 95% CI
Freudenreich 2009 (1)	0	19	1	16	32.9%	0.28	[0.01, 6.51]	
Lehr 2013 (2)	0	12	1	12	33.5%	0.33	[0.01, 7.45]	
Seyv 2005 (3)	1	13	0	11	33.5%	2.57	[0.12, 57.44]	
Total (95% CI)	1	44	2	39	100.0%	0.63	[0.10, 3.79]	

Total events: 1 (non-stimulant), 2 (Placebo)

Heterogeneity: Tau² = 0.00; Chi² = 1.20, df = 2 (P = 0.55); I² = 0%


Test for overall effect: Z = 0.51 (P = 0.61)

Footnotes

(1) Modafinil

(2) Modafinil

(3) Modafinil



Risk of bias legend